Pterostilbene for Stage IV Cancer
Also known as: Dimethylresveratrol, trans-3,5-Dimethoxy-4'-hydroxystilbene
Pterostilbene's improved bioavailability over resveratrol may achieve anti-cancer tissue concentrations more reliably.
Mechanism of Action
Pterostilbene inhibits NF-κB, STAT3, and PI3K/Akt survival signaling, induces apoptosis and autophagy in cancer cells, inhibits angiogenesis, and modulates epigenetic enzymes. Its superior oral bioavailability (80% vs 20% for resveratrol) enhances clinical potential.
General mechanism: Dimethylated stilbenoid. SIRT1 activator (4x bioavailability of resveratrol), Nrf2 activator, NF-κB inhibitor, epigenetic modulator.
Current Evidence
Preclinical evidence across colon, breast, prostate, and pancreatic cancer. Better tissue distribution than resveratrol. Clinical trials emerging.
Clinical Status: Preclinical positive. Phase I for cancer prevention. Available as supplement.
Safety Profile
Very safe. Well-tolerated at 250mg/day in clinical trials. No significant side effects. Present in blueberries.
Key Research Questions
- Does pterostilbene achieve anti-cancer tissue concentrations in humans?
- Can pterostilbene enhance chemotherapy through epigenetic modulation?